Detail Data
Volume (24h): 1,655,108 shares
P/E Ratio: /
Forward P/E: -9.38
EPS: -1.03 USD
Forward EPS: -0.48 USD
Number of Shares: 77,114,600 shares
Market Capitalization: 347,015,712.00 USD

Dividend

Dividend Value
Dividend Amount According to our data, the company Corvus Pharmaceuticals does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a strong_buy recommendation for Corvus Pharmaceuticals stock. The current number of analysts covering this company is 5. The highest target price is 24 USD, while the lowest target price is 11 USD. The median target valuation set by analysts is 13 USD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Corvus Pharmaceuticals.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Corvus Pharmaceuticals stock is: strong_buy
Number of Analysts: 5
Highest Target Price: 24 USD
Lowest Target Price: 11 USD
Median Target Price: 13 USD

Fundamental Indicators

Indicator Data
Total Revenue: /
Net Income: -41,399,000.00 USD
Price-to-Book (P/B): 6.22
PEG Ratio: /
Exchange: NasdaqGM
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 31
Country: United States

Where to Buy Corvus Pharmaceuticals Stock?

You can purchase Corvus Pharmaceuticals stock on the NasdaqGM under the ticker symbol: CRVS. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Corvus Pharmaceuticals Stock

Indicator Value
Company Revenue: -
EBITDA: -31,133,000.00 USD - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -1.03 USD
Book Value Per Share: 0.72 USD
Total Cash: 44,212,000.00 USD
Total Cash per Share: 0.57 USD
Total Debt: 1,153,000.00 USD
Debt to Equity Ratio: 0.02
Quick Ratio 4.79
Current Ratio 4.90
Free Cash Flow -13,173,625.00 USD
Operating Cash Flow -28,530,000.00 USD
Gross Margins -
EBITDA Margins -
Operating Margins -
Profit Margins -
Return on Assets -39.2 %
Return on Equity -100.1 %
Earnings Growth (1 year) -
Revenue Growth (1 year) -
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 347,015,712.00 USD
Enterprise Value 303,956,864.00 USD
EV/Revenue -
EV/EBITDA -9.763
Float Shares 63,154,573 shares
Shares Outstanding 77,114,600 shares
Held Percent Insiders 0.04 %
Held Percent Institutions 49.07 %
Shares Short 7,080,956
Shares Short Prior Month 5,774,289
Date Short Interest 2025-05-30
Short Percentage of Total Shares 9.18 %
Short Ratio 5.23
Beta 0.58
Short Percentage of Float 11.52 %
Implied Shares Outstanding 77,114,600

Frequently Asked Questions (FAQ)

According to our data, the company Corvus Pharmaceuticals does not pay dividends yet, even in 2025.

Corvus Pharmaceuticals shares are traded on the NasdaqGM stock exchange under the ticker: CRVS. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Corvus Pharmaceuticals shares is from a total of 5 analysts. The average target price prediction is 13 USD per share.

The total number of Corvus Pharmaceuticals shares on the exchange is 77,114,600.00 shares, which at the current market capitalization gives the company a total valuation of 347,015,712.00 USD.